

SEQUENCE LISTING

<110> University of Zurich

<120> Monoclonal amyloid beta (Abeta)-specific antibody and uses thereof

<130> NE30A12/P-WO

<150> 60/993,749

<151> 2007-09-13

<160> 11

<170> PatentIn version 3.5

<210> 1

<211> 12

<212> PRT

<213> Artificial

<220>

<223> Peptide

<220>

<221> PEPTIDE

<222> (1)..(12)

<223> Epitope of anti-amyloid beta peptide (Abeta) recognized by antibody NI-103

<400> 1

Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val

1

5

10

<210> 2

<211> 366

<212> DNA

<220>

<221> CDS

<222> (1) .. (366)

<223> NI-103 variable heavy (Vh) chain sequence

<400> 2

gag gtc cag ctg cat cag tct gga cct gaa ctg gtg aag cct ggg gct 48
Glu Val Gln Leu His Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15

tca gtg aag ata tcc tgc aag act tct gga tac aca ttc act gaa tac 96
Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr
20 25 30

acc atg cac tgg gtg aaa cag agc cat gga aag agc ctt gag tgg att 144
Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
35 40 45

gga ggt gtt aat cct tac aat gat aat act tct tac atc cgg aag tta 192
Gly Gly Val Asn Pro Tyr Asn Asp Asn Thr Ser Tyr Ile Arg Lys Leu
50 55 60

cag ggc aag gtc aca ttg act gta gac agg tcc tcc agc aca gcc tac 240
Gln Gly Lys Val Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr
65 70 75 80

atg gag ctc cgc agc ctg aca tct gag gat tct gca gtc tat ttc tgt 288
Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95

gca aga tac ggg gga tta cgc cct tat tac ttt cct atg gac ttc tgg 336
Ala Arg Tyr Gly Gly Leu Arg Pro Tyr Tyr Phe Pro Met Asp Phe Trp
100 105 110

ggt caa gga acc tca gtc acc gtc tcc tca 366
 Gly Gln Gly Thr Ser Val Thr Val Ser Ser
 115 120

<210> 3
 <211> 122
 <212> PRT
 <213> Mus musculus

<400> 3

Glu Val Gln Leu His Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr
 20 25 30

Thr Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
 35 40 45

Gly Gly Val Asn Pro Tyr Asn Asp Asn Thr Ser Tyr Ile Arg Lys Leu
 50 55 60

Gln Gly Lys Val Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 85 90 95

Ala Arg Tyr Gly Gly Leu Arg Pro Tyr Tyr Phe Pro Met Asp Phe Trp
 100 105 110

Gly Gln Gly Thr Ser Val Thr Val Ser Ser
 115 120

<210>	4
<211>	321
<212>	DNA
<213>	Mus musculus

```
<220>
<221> CDS
<222> (1)..(321)
<223> NI-103 variable light (V1) chain sequence
```

<400>	4															
caa gtt gtt ctc tcc cag tct cca gca atc ctg tct gca tct cca ggg	48															
Gln Val Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly																
1 5 10 15																
gag agg gtc aca ctg act tgc agg gcc agc tca agt gta aat tac atg	96															
Glu Arg Val Thr Leu Thr Cys Arg Ala Ser Ser Ser Val Asn Tyr Met																
20 25 30																
cac tgg tac cag cag aag cca gga tcc tcc ccc aaa gcc tgg att tat	144															
His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Ala Trp Ile Tyr																
35 40 45																
gcc aca tcc aac ctg gct tct gga gtc cct gat cgc ttc agt gcc agt	192															
Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Ala Ser																
50 55 60																
ggg tct ggg acc tct tac tct ctc aca atc agc aga gtg gag gct gaa	240															
Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu																
65 70 75 80																
gat gct gcc act tat tac tgt cag cag tgg aga act aac cca cct acg	288															
Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Arg Thr Asn Pro Pro Thr																
85 90 95																
ttc ggt gct ggg acc aag ctg gag ctg aaa cgg	321															
Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg																
100 105																

<210> 5
 <211> 107
 <212> PRT
 <213> Mus musculus

<400> 5

Gln Val Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly
 1 5 10 15

Glu Arg Val Thr Leu Thr Cys Arg Ala Ser Ser Ser Val Asn Tyr Met
 20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Ala Trp Ile Tyr
 35 40 45

Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Ala Ser
 50 55 60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu
 65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Arg Thr Asn Pro Pro Thr
 85 90 95

Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg
 100 105

<210> 6
 <211> 10
 <212> PRT

<213> Artificial

<220>

<223> complementarity determining region (CDR)

<220>

<221> MISC_FEATURE

<222> (1)..(10)

<223> Denomination of CDR protein sequences in Kabat Nomenclature of
NI-103 CDRH1

<400> 6

Gly Tyr Thr Phe Thr Glu Tyr Thr Met His

1 5 10

<210> 7

<211> 17

<212> PRT

<213> Artificial

<220>

<223> complementarity determining region (CDR)

<220>

<221> MISC_FEATURE

<222> (1)..(17)

<223> Denomination of CDR protein sequences in Kabat Nomenclature of
NI-103 CDRH2

<400> 7

Gly Val Asn Pro Tyr Asn Asp Asn Thr Ser Tyr Ile Arg Lys Leu Gln

1 5 10 15

Gly

<210> 8
 <211> 13
 <212> PRT
 <213> Artificial

<220>

<223> complementarity determining region (CDR)

<220>

<221> MISC_FEATURE

<222> (1)..(13)

<223> Denomination of CDR protein sequences in Kabat Nomenclature of
 NI-103 CDRH3

<400> 8

Tyr Gly Gly Leu Arg Pro Tyr Tyr Phe Pro Met Asp Phe
 1 5 10

<210> 9
 <211> 10
 <212> PRT
 <213> Artificial

<220>

<223> complementarity determining region (CDR)

<220>

<221> MISC_FEATURE

<222> (1)..(10)

<223> Denomination of CDR protein sequences in Kabat Nomenclature of
 NI-103 CDRL1

<400> 9

Arg Ala Ser Ser Ser Val Asn Tyr Met His
 1 5 10

<210> 10
<211> 7
<212> PRT
<213> Artificial

<220>
<223> complementarity determining region (CDR)

<220>
<221> MISC_FEATURE
<222> (1)..(7)
<223> Denomination of CDR protein sequences in Kabat Nomenclature of
NI-103 CDRL2

<400> 10

Ala Thr Ser Asn Leu Ala Ser .
1 5

<210> 11
<211> 9
<212> PRT
<213> Artificial

<220>
<223> complementarity determining region (CDR)

<220>
<221> MISC_FEATURE
<222> (1)..(9)
<223> Denomination of CDR protein sequences in Kabat Nomenclature of
NI-103 CDRL3

<400> 11

Gln Gln Trp Arg Thr Asn Pro Pro Thr
1 5